1 day Ago By Defense World Staff
Renaissance Technologies LLC grew its stake in shares of Inozyme Pharma, Inc. (NASDAQ:INZY – Free Report) by 155.7% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission.
The institutional investor owned 421,399 shares of the company’s stock after purchasing an additional 256,599 shares during the period. Renaissance Technologies LLC owned approximately 0.66% of Inozyme Pharma worth $1,167,000 as of its most recent SEC filing.
Other hedge funds and other institutional investors also recently modified their holdings of the company. abrdn plc purchased a new position in shares of Inozyme Pharma in the 4th quarter valued at approximately $472,000. Knott David M Jr raised its holdings in Inozyme Pharma by 23.
1% in the fourth quarter. Knott David M Jr now owns 695,000 shares of the company’s stock worth $1,925,000 after purchasing an additional 130,451 shares in the last quarter. JPMorgan Chase & Co.
lifted its position in Inozyme Pharma by 345.5% during the fourth quarter. JPMorgan Chase & Co.
now owns 128,872 shares of the company’s stock valued at $357,000 after buying an additional 99,944 shares during the period. ADAR1 Capital Management LLC bought a new stake in shares of Inozyme Pharma during the 4th quarter valued at $211,000. Finally, Raymond James Financial Inc.
purchased a new stake in shares of Inozyme Pharma in the 4th quarter worth about $205,000. Hedge funds and other institutional investors own 88.30% of the company’s stock.
Inozyme Pharma Stock Up 9.9 %INZY stock opened at $1.06 on Wednesday.
The company has a debt-to-equity ratio of 0.51, a current ratio of 7.68 and a quick ratio of 7.
68. Inozyme Pharma, Inc. has a 1-year low of $0.
72 and a 1-year high of $6.24. The stock has a market capitalization of $68.
09 million, a P/E ratio of -0.68 and a beta of 1.39.
The business has a fifty day moving average price of $1.01 and a 200-day moving average price of $2.19.
Wall Street Analysts Forecast GrowthINZY has been the subject of a number of recent research reports. Wells Fargo & Company lowered their price target on shares of Inozyme Pharma from $14.00 to $11.
00 and set an “overweight” rating for the company in a research report on Monday, January 13th. Needham & Company LLC reissued a “buy” rating and issued a $15.00 price target on shares of Inozyme Pharma in a research report on Tuesday, April 8th.
Wedbush reaffirmed an “outperform” rating and set a $7.00 price objective (down previously from $12.00) on shares of Inozyme Pharma in a research report on Monday, March 10th.
HC Wainwright reissued a “buy” rating and issued a $16.00 target price on shares of Inozyme Pharma in a report on Thursday, April 10th. Finally, Piper Sandler reduced their price target on Inozyme Pharma from $30.
00 to $23.00 and set an “overweight” rating for the company in a report on Tuesday, March 11th. Eight analysts have rated the stock with a buy rating, According to data from MarketBeat.
com, the company has an average rating of “Buy” and an average price target of $14.63.Get Our Latest Stock Analysis on INZYInozyme Pharma Profile (Free Report)Inozyme Pharma, Inc, a clinical-stage rare disease biopharmaceutical company, focuses on developing novel therapeutics for the treatment of vasculature, soft tissue, and skeleton diseases.
The company's lead product candidate is INZ-701, a soluble, recombinant, genetically engineered, and fusion protein for the treatment of ENPP1 and ABCC6 deficiencies, as well as patients with end-stage kidney disease receiving hemodialysis.See AlsoFive stocks we like better than Inozyme Pharma2 Rising CRM Platform Stocks That Can Surge Higher in 2025 Don’t Be Fooled by the Bounce: The Market Storm Isn’t Over YetWhat Are Dividend Champions? How to Invest in the ChampionsCoca-Cola Company Stock Can Bubble to New Highs This YearTrading Halts Explained3 Stocks Lifting 2025 Guidance Despite Market Jitters.
